Fundamental Analysis of ERYTECH PHARMA - SPON ADR(NASDAQ:ERYP) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ERYP. ERYP was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of ERYP have multiple concerns. ERYP is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ERYP has reported negative net income.

In the past year ERYP has reported a negative cash flow from operations.

ERYP had negative earnings in each of the past 5 years.

ERYP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The profitability ratios for ERYP are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ERYP so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ERYP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ERYP has about the same amount of shares outstanding.

The number of shares outstanding for ERYP has been increased compared to 5 years ago.

Compared to 1 year ago, ERYP has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.54, we must say that ERYP is in the distress zone and has some risk of bankruptcy.

ERYP has a Altman-Z score (-2.54) which is comparable to the rest of the industry.

A Debt/Equity ratio of 0.44 indicates that ERYP is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.44, ERYP is doing worse than 71.50% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.44
Debt/FCF	N/A
Altman-Z	-2.54

ROIC/WACCN/A

WACC4.93%

2.3 Liquidity

A Current Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.

With a Current ratio value of 3.65, ERYP is not doing good in the industry: 61.67% of the companies in the same industry are doing better.

A Quick Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.

ERYP's Quick ratio of 3.65 is on the low side compared to the rest of the industry. ERYP is outperformed by 60.71% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.65
Quick Ratio	3.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ERYP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.68%, which is quite impressive.

Looking at the last year, ERYP shows a very strong growth in Revenue. The Revenue has grown by 59.04%.

ERYP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.60% yearly.

EPS 1Y (TTM)99.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%102.44%

Revenue 1Y (TTM)59.04%

Revenue growth 3Y7.96%

Revenue growth 5Y14.6%

Sales Q2Q%198.12%

3.2 Future

Based on estimates for the next years, ERYP will show a very strong growth in Earnings Per Share. The EPS will grow by 26.28% on average per year.

Based on estimates for the next years, ERYP will show a very negative growth in Revenue. The Revenue will decrease by -44.77% on average per year.

EPS Next Y22.35%

EPS Next 2Y26.28%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year16.44%

Revenue Next 2Y16.85%

Revenue Next 3Y-56.11%

Revenue Next 5Y-44.77%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERYP. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ERYP. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ERYP's earnings are expected to grow with 26.28% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.28%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ERYP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ERYTECH PHARMA - SPON ADR

NASDAQ:ERYP (6/28/2023, 8:00:02 PM)

0.78

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap26.61M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.17

Health

		Industry Rank	Sector Rank
Debt/Equity	0.44
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.65
Quick Ratio	3.65
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)99.68%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y22.35%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)59.04%

Revenue growth 3Y7.96%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ERYTECH PHARMA - SPON ADR (ERYP)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens